Lumos Pharma Stock Revenue
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
Lumos |
Lumos Pharma Company Revenue Analysis
Lumos Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Lumos Pharma Revenue | 2.05 M |
Most of Lumos Pharma's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Lumos Pharma reported 2.05 M of revenue. This is 99.97% lower than that of the Biotechnology sector and 99.72% lower than that of the Health Care industry. The revenue for all United States stocks is 99.98% higher than that of the company.
Lumos Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in revenue category among its peers.
Lumos Fundamentals
Return On Equity | -1.73 | |||
Return On Asset | -0.7 | |||
Operating Margin | (10.52) % | |||
Current Valuation | 24.19 M | |||
Shares Outstanding | 8.65 M | |||
Shares Owned By Insiders | 32.69 % | |||
Shares Owned By Institutions | 24.27 % | |||
Number Of Shares Shorted | 54.33 K | |||
Price To Earning | (2.37) X | |||
Price To Book | 7.64 X | |||
Price To Sales | 17.02 X | |||
Revenue | 2.05 M | |||
Gross Profit | 1.52 M | |||
EBITDA | (36.57 M) | |||
Net Income | (34.03 M) | |||
Cash And Equivalents | 79.51 M | |||
Cash Per Share | 9.49 X | |||
Total Debt | 585 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 17.59 X | |||
Book Value Per Share | 0.57 X | |||
Cash Flow From Operations | (31.09 M) | |||
Short Ratio | 0.59 X | |||
Earnings Per Share | (4.28) X | |||
Price To Earnings To Growth | (0.15) X | |||
Target Price | 4.25 | |||
Number Of Employees | 30 | |||
Beta | 0.33 | |||
Market Capitalization | 37.54 M | |||
Total Asset | 40.64 M | |||
Retained Earnings | (161.52 M) | |||
Working Capital | 33.01 M | |||
Current Asset | 115.78 M | |||
Current Liabilities | 14.4 M | |||
Net Asset | 40.64 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |